Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(34)
DRUG(9)
PROCEDURE(3)
DIAGNOSTIC_TEST(1)
Vincristine
2 trials
phase_1phase_2
national-cancer-institute-nci
Cyclophosphamide
2 trials
phase_1phase_2
national-cancer-institute-nci
MRI
2 trials
phase_1phase_2
national-cancer-institute-nci
Bone Marrow Aspiration
2 trials
phase_1
national-cancer-institute-nci
Rituximab
2 trials
phase_1phase_2
national-cancer-institute-nci
Prednisone
2 trials
phase_1phase_2
national-cancer-institute-nci
Etoposide
2 trials
phase_1phase_2
national-cancer-institute-nci
Doxorubicin
2 trials
phase_1phase_2
national-cancer-institute-nci

+31 more interventions

39 unique interventions5 categories

Analytics

Trial Phases

Phase 13
Phase 24

Trial Status

Completed5
Terminated3

Role Distribution

Principal Investigator8
PI Rate100%

Activity Timeline

Clinical Trials (8)

NCT04933617Phase 1Terminated
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Burkitt LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Germinal Center B-cell Type (GCB)+2 more
PrincipalinvestigatorStart date: 2022-03-24
NCT04599634Phase 1Completed
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
B-Cell LymphomaChronic Lymphocytic LymphomaFollicular Lymphoma+2 more
PrincipalinvestigatorStart date: 2021-12-16
NCT03255018Phase 2Completed
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Diffuse Large B-Cell LymphomaGray-zone LymphomaLymphoma+2 more
PrincipalinvestigatorStart date: 2018-02-15
NCT01248455Phase 2Terminated
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Multiple MyelomaMyelomaSmoldering Multiple Myeloma
PrincipalinvestigatorStart date: 2010-11-01
NCT01109407Terminated
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Myeloma
PrincipalinvestigatorStart date: 2010-04-22
NCT01092182Phase 2Completed
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Burkitt LymphomaDiffuse Large B-cell Lymphoma, c-MYC PositivePlasmablastic Lymphoma
PrincipalinvestigatorStart date: 2010-03-25
NCT00001337Phase 2Completed
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large-Cell LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)+2 more
PrincipalinvestigatorStart date: 1993-05-08
NCT00861510Phase 1Completed
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Leukemia, Hairy CellLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-cell+2 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Lymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Hairy Cell+4 more

Worked with same sponsors:

National Cancer Institute (NCI)National Heart, Lung, and Blood Institute (NHLBI)
Similarity Score8%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Multiple MyelomaLymphomaLymphoma, Follicular+4 more

Worked with same sponsors:

National Cancer Institute (NCI)National Heart, Lung, and Blood Institute (NHLBI)
Similarity Score8%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Multiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell+3 more
Similarity Score7%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLeukemia, Hairy Cell+3 more
Similarity Score7%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell+2 more

Worked with same sponsors:

National Heart, Lung, and Blood Institute (NHLBI)
Similarity Score6%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma+1 more
Similarity Score4%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinMultiple MyelomaPrimary Central Nervous System Lymphoma+1 more
Similarity Score4%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, Non-Hodgkin
Similarity Score3%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score3%

David Cunningham

Royal Marsden NHS Foundation Trust

Related
13 trials

Shared therapeutic areas:

Lymphoma, B-CellLymphomaLymphoma, Non-Hodgkin
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (8)

Showing 8 of 8 trials

NCT04933617Phase 1PrincipalInvestigator

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Burkitt LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Germinal Center B-cell Type (GCB)+2 more
Terminated
NCT04599634Phase 1PrincipalInvestigator

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

B-Cell LymphomaChronic Lymphocytic LymphomaFollicular Lymphoma+2 more
Completed
NCT03255018Phase 2PrincipalInvestigator

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Diffuse Large B-Cell LymphomaGray-zone LymphomaLymphoma+2 more
Completed
NCT01248455Phase 2PrincipalInvestigator

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

Multiple MyelomaMyelomaSmoldering Multiple Myeloma
Terminated
NCT01109407PrincipalInvestigator

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Myeloma
Terminated
NCT01092182Phase 2PrincipalInvestigator

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Burkitt LymphomaDiffuse Large B-cell Lymphoma, c-MYC PositivePlasmablastic Lymphoma
Completed
NCT00001337Phase 2PrincipalInvestigator

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Anaplastic Large-Cell LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)+2 more
Completed
NCT00861510Phase 1PrincipalInvestigator

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

Leukemia, Hairy CellLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-cell+2 more
Completed

All 8 trials loaded